Do you want to read an article? Please log in or register.
ENGOT-EN6-NSGO/GOG-3031/RUBY: Post hoc analyses show sustained survival benefit with dostarlimab plus chemotherapy in dMMR/MSI-H endometrial cancer
Genitourinary Cancer
CHICAGO 2026
Related content
SPECIAL REPORT
Gynecologic Cancer
Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer
CHICAGO 2025
Gynecologic Cancer
RUBY: Dostarlimab plus carboplatin and paclitaxel shows no detrimental effect on QoL in patients with primary advanced or recurrent endometrial cancer
WCLC 2025
Lung, Respiratory and Thoracic Cancer
EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC
ESMO 2025
Gastrointestinal Cancer
CheckMate 8HW: Nivolumab plus ipilimumab provides clinically meaningful benefits over nivolumab alone in MSI-H/dMMR-positive mCRC
SABCS 2025
Breast Cancer
NATALEE: Long-term data show sustained clinical benefit with ribociclib plus an NSAI in HR-positive, HER2-negative early breast cancer
CHICAGO 2026
Genitourinary Cancer
EV-302: The 3.5-year update shows that enfortumab vedotin plus pembrolizumab maintains durable survival benefit over chemotherapy in advanced urothelial carcinoma
ESMO 2025
Breast Cancer
NATALEE: Ribociclib plus adjuvant endocrine therapy sustains iDFS benefit two years post-treatment in patients with HR+/HER2− breast cancer
Gastrointestinal Cancer
Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial
Eur J Cancer
Bergen ES, Canton C, Boulin M, Le Malicot K, Bennouna J, Gonzalez D, Mineur L, Bouche O, Lepage C, Taieb J
doi: 10.1016/j.ejca.2025.115643
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Kinehara Y, Matsumoto K, Shiroyama T, Komuta K, Tamiya M, Nishino K, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A
doi: 10.1016/j.lungcan.2026.109336